WEKO3
インデックスリンク
アイテム
{"_buckets": {"deposit": "27b16c02-6537-473c-8f02-b68f8c37cd80"}, "_deposit": {"created_by": 3, "id": "14495", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "14495"}, "status": "published"}, "_oai": {"id": "oai:kanazawa-u.repo.nii.ac.jp:00014495", "sets": ["1134"]}, "author_link": ["71", "24460", "25437", "25439", "20436", "25438", "25441", "25440", "235"], "item_4_biblio_info_8": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2011-06-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "6", "bibliographicPageEnd": "545", "bibliographicPageStart": "541", "bibliographicVolumeNumber": "86", "bibliographic_titles": [{"bibliographic_title": "European Journal of Haematology"}]}]}, "item_4_description_21": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "A 1-yr-old Japanese male infant developed hepatitis-associated aplastic anemia (AA), and anti-thymocyte globulin (ATG) plus cyclosporine A (CsA) was administered without any appreciable effects. Laboratory examination of the patient\u0027s serum obtained before therapy revealed various autoantibodies, such as PA-IgG, anti-platelets, anti-single-stranded DNA (ssDNA), and anti-double-stranded DNA (dsDNA) antibodies (Abs) in addition to anti-DRS-1 Abs and anti-moesin Abs, both of which are known to be detectable in approximately 40% of all patients presenting with AA. He was therefore treated with 17.5mg/kg/d rituximab 5.5months after ATG/CsA therapy. The same rituximab therapy was repeated three times once a month thereafter. His neutrophil counts started to increase 50d after the first rituximab therapy and he achieved a complete remission at 16months after the last rituximab administration. All of the autoantibodies including anti-ssDNA, dsDNA, DRS-1, and moesin became undetectable when he attained the remission. Anti-CD20 monoclonal antibody therapy may be effective in a subset of patients with AA characterized by the presence of autoantibodies. © 2011 John Wiley \u0026 Sons A/S.", "subitem_description_type": "Abstract"}]}, "item_4_description_5": {"attribute_name": "提供者所属", "attribute_value_mlt": [{"subitem_description": "金沢大学医薬保健研究域医学系", "subitem_description_type": "Other"}]}, "item_4_publisher_17": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Wiley-Blackwell"}]}, "item_4_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1111/j.1600-0609.2011.01612.x", "subitem_relation_type_select": "DOI"}}]}, "item_4_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AA10668976", "subitem_source_identifier_type": "NCID"}]}, "item_4_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0902-4441", "subitem_source_identifier_type": "ISSN"}]}, "item_4_version_type_25": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Takamatsu, Hiroyuki"}], "nameIdentifiers": [{"nameIdentifier": "24460", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "70401932", "nameIdentifierScheme": "金沢大学研究者情報", "nameIdentifierURI": "http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=70401932"}, {"nameIdentifier": "70401932", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000070401932"}]}, {"creatorNames": [{"creatorName": "Yagasaki, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "25437", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takahashi, Yoshiyuki"}], "nameIdentifiers": [{"nameIdentifier": "25438", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hama, Asahito"}], "nameIdentifiers": [{"nameIdentifier": "25439", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Saikawa, Yutaka"}], "nameIdentifiers": [{"nameIdentifier": "25440", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "60283107", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=60283107"}, {"nameIdentifier": "60283107", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000060283107"}]}, {"creatorNames": [{"creatorName": "Yachie, Akihiro"}], "nameIdentifiers": [{"nameIdentifier": "20436", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "40210281", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=40210281"}, {"nameIdentifier": "40210281", "nameIdentifierScheme": "金沢大学研究者情報", "nameIdentifierURI": "http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=40210281"}, {"nameIdentifier": "40210281", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000040210281"}]}, {"creatorNames": [{"creatorName": "Koizumi, Shoichi"}], "nameIdentifiers": [{"nameIdentifier": "235", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "50019973", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=50019973"}, {"nameIdentifier": "50019973", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000050019973"}]}, {"creatorNames": [{"creatorName": "Kojima, Seiji"}], "nameIdentifiers": [{"nameIdentifier": "25441", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakao, Shinji"}], "nameIdentifiers": [{"nameIdentifier": "71", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "70217660", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=70217660"}, {"nameIdentifier": "70217660", "nameIdentifierScheme": "金沢大学研究者情報", "nameIdentifierURI": "http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=70217660"}, {"nameIdentifier": "70217660", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000070217660"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-10-03"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "ME-PR-TAKAMATSU-H-541.pdf", "filesize": [{"value": "391.3 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 391300.0, "url": {"label": "ME-PR-TAKAMATSU-H-541.pdf", "url": "https://kanazawa-u.repo.nii.ac.jp/record/14495/files/ME-PR-TAKAMATSU-H-541.pdf"}, "version_id": "3fc46946-b7b5-47e4-9742-3310d57d89a1"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Aplastic anemia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Autoantibody", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Rituximab", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Aplastic anemia successfully treated with rituximab: The possible role of aplastic anemia-associated autoantibodies as a marker for response", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Aplastic anemia successfully treated with rituximab: The possible role of aplastic anemia-associated autoantibodies as a marker for response"}]}, "item_type_id": "4", "owner": "3", "path": ["1134"], "permalink_uri": "http://hdl.handle.net/2297/28340", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-10-03"}, "publish_date": "2017-10-03", "publish_status": "0", "recid": "14495", "relation": {}, "relation_version_is_last": true, "title": ["Aplastic anemia successfully treated with rituximab: The possible role of aplastic anemia-associated autoantibodies as a marker for response"], "weko_shared_id": -1}
Aplastic anemia successfully treated with rituximab: The possible role of aplastic anemia-associated autoantibodies as a marker for response
http://hdl.handle.net/2297/28340
http://hdl.handle.net/2297/2834067e11b1b-36eb-4dfc-82cc-43c0bb5e7d95
名前 / ファイル | ライセンス | アクション |
---|---|---|
ME-PR-TAKAMATSU-H-541.pdf (391.3 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-10-03 | |||||
タイトル | ||||||
タイトル | Aplastic anemia successfully treated with rituximab: The possible role of aplastic anemia-associated autoantibodies as a marker for response | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Takamatsu, Hiroyuki
× Takamatsu, Hiroyuki× Yagasaki, Hiroshi× Takahashi, Yoshiyuki× Hama, Asahito× Saikawa, Yutaka× Yachie, Akihiro× Koizumi, Shoichi× Kojima, Seiji× Nakao, Shinji |
|||||
提供者所属 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 金沢大学医薬保健研究域医学系 | |||||
書誌情報 |
European Journal of Haematology 巻 86, 号 6, p. 541-545, 発行日 2011-06-01 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0902-4441 | |||||
NCID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA10668976 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1111/j.1600-0609.2011.01612.x | |||||
出版者 | ||||||
出版者 | Wiley-Blackwell | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | A 1-yr-old Japanese male infant developed hepatitis-associated aplastic anemia (AA), and anti-thymocyte globulin (ATG) plus cyclosporine A (CsA) was administered without any appreciable effects. Laboratory examination of the patient's serum obtained before therapy revealed various autoantibodies, such as PA-IgG, anti-platelets, anti-single-stranded DNA (ssDNA), and anti-double-stranded DNA (dsDNA) antibodies (Abs) in addition to anti-DRS-1 Abs and anti-moesin Abs, both of which are known to be detectable in approximately 40% of all patients presenting with AA. He was therefore treated with 17.5mg/kg/d rituximab 5.5months after ATG/CsA therapy. The same rituximab therapy was repeated three times once a month thereafter. His neutrophil counts started to increase 50d after the first rituximab therapy and he achieved a complete remission at 16months after the last rituximab administration. All of the autoantibodies including anti-ssDNA, dsDNA, DRS-1, and moesin became undetectable when he attained the remission. Anti-CD20 monoclonal antibody therapy may be effective in a subset of patients with AA characterized by the presence of autoantibodies. © 2011 John Wiley & Sons A/S. | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa |